Diane L. Dewbrey - 29 Sep 2023 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Role
Director
Signature
/s/ Andrew P. Campbell as attorney-in-fact for Diane L. Dewbrey
Issuer symbol
COCH
Transactions as of
29 Sep 2023
Net transactions value
$0
Form type
4
Filing time
03 Oct 2023, 21:42:19 UTC
Previous filing
16 May 2023
Next filing
16 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANZU Class A Common Stock, par value $0.0001 per share Conversion of derivative security $0 +25,000 $0.000000 25,000 29 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANZU Class B Common Stock, par value $0.0001 per share Conversion of derivative security $0 -25,000 -100% $0.000000* 0 29 Sep 2023 Class A Common Stock, par value $0.0001 per share 25,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Diane L. Dewbrey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On September 29, 2023, in connection with the consummation of the business combination (the "Business Combination") between Anzu Special Acquisition Corp I ("Anzu") and Envoy Medical Corporation, each share of Class B Common Stock, par value $0.0001 per share, automatically converted into one share of Class A Common Stock, par value $0.0001 per share. In connection with the Business Combination, Ms. Dewbrey resigned as a director of Anzu.